| Grant number: | 25/15952-4 |
| Support Opportunities: | Research Grants - Young Investigators Grants - Phase 2 |
| Start date: | August 01, 2026 |
| End date: | July 31, 2031 |
| Field of knowledge: | Humanities - Psychology - Psychological Treatment and Prevention |
| Principal Investigator: | Renatha El Rafihi Ferreira |
| Grantee: | Renatha El Rafihi Ferreira |
| Host Institution: | Instituto de Psicologia (IP). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
| City of the host institution: | São Paulo |
| Associated researchers: | Charles M. Morin ; Daniel Graça Fatori de Sá ; Rosa Hasan ; Suzanne Michele Bertisch |
| Associated research grant: | 18/19506-5 - Acceptance and commitment therapy for insomnnia, AP.JP |
Abstract
Insomnia is a highly prevalent public health issue with significant consequences for health, well-being, and individual and societal productivity. Although clinical guidelines recommend cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, pharmacological therapy with hypnotics remains the most commonly used approach worldwide. Hypnotics provide short-term relief but are frequently associated with cognitive impairment, tolerance, dependence, and a lack of long-term benefit. An estimated 30% to 50% of patients with chronic insomnia do not achieve full remission with standard treatments such as CBT-I or hypnotics. These nonresponders often continue to experience functional impairment, long-term medication use, and increased risk for psychiatric comorbidities, resulting in avoidable chronic costs. Adaptive strategies that integrate psychotherapy and pharmacotherapy, particularly with a focus on supervised discontinuation of hypnotics, remain limited. This study proposes a SMART (Sequential, Multiple Assignment, Randomized Trial) design to evaluate personalized treatment trajectories for chronic insomnia. Participants will initially be randomized to receive either Brief Behavioral Treatment for Insomnia (BBTI) or Zolpidem for 6 weeks. Nonresponders will be rerandomized to Acceptance and Commitment Therapy for Insomnia (ACT-I) or full CBT-I. Responders to Zolpidem will be rerandomized to ACT-I + supervised tapering or CBT-I + supervised tapering. This is the first adaptive study to integrate ACT-I both as a second-line intervention and as a strategy to support hypnotic withdrawal, combining methodological innovation with high clinical applicability and potential impact on sleep health policy. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |